Calypte Biomedical Corporation (OTCBB: CBMC), a Portland, Oregon company that develops, manufactures and markets HIV diagnostic tests, said its Chinese subsidiary, Beijing Marr Bio-pharmaceutical Co., Ltd., received an SFDA permit to manufacture in vitro diagnostic tests. Calypte is awaiting approval from the SFDA for its rapid oral HIV test. Once approval is secured, Calypte will manufacture the diagnostic test for China and international markets at the Beijing Marr facility. Calypte's Aware™ HIV-1/2 OMT rapid diagnostic test uses oral fluids to diagnose HIV-1 or HIV-2 infection in 20 minutes with high accuracy. More details...

Stock Symbol: (OTCBB: CBMC)